Lanreotide 60 mg, a Longer-Acting Somatostatin Analog: Tumor Shrinkage and Hormonal Normalization in Acromegaly

@article{Cozzi2000Lanreotide6M,
  title={Lanreotide 60 mg, a Longer-Acting Somatostatin Analog: Tumor Shrinkage and Hormonal Normalization in Acromegaly},
  author={Renato Cozzi and Michela Barausse and Maurizio Sberna and Alessandro Lodrini and Angelo Franzini and G. Lasio and Roberto Attanasio},
  journal={Pituitary},
  year={2000},
  volume={3},
  pages={231-238}
}
Background: Somatostatin analogues are nowadays the milestone in the medical treatment of acromegaly. We evaluated the effects of a new 60 mg longer-acting formulation of lanreotide (LAN60) on GH/IGF-I levels and tumor size. Patients: Twenty-one acromegalics entered a prospective monocentric open study. Eight were consecutive “de novo” patients (group I). Thirteen patients sensitive to SA (GH levels < 2.5 μg/l and/or IGF-I normalization on chronic LAN 30 mg (LAN30) treatment) were switched to… CONTINUE READING